Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
Authors
Keywords
Navitoclax, Irinotecan, Pharmacokinetic parameters, Bcl-2 inhibitor, Safety
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 76, Issue 5, Pages 1041-1049
Publisher
Springer Nature
Online
2015-10-01
DOI
10.1007/s00280-015-2882-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
- (2014) James M. Cleary et al. INVESTIGATIONAL NEW DRUGS
- Merkel Cell Carcinoma Dependence on Bcl-2 Family Members for Survival
- (2014) Monique E. Verhaegen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer
- (2014) Xiang Liu et al. PHARMACOGENOMICS
- Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumoursin vivo
- (2012) S Ackler et al. BRITISH JOURNAL OF PHARMACOLOGY
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
- (2012) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL
- (2011) J. Shi et al. CANCER RESEARCH
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Mitochondrial signaling in cell death via the Bcl-2 family
- (2010) Brian Leibowitz et al. CANCER BIOLOGY & THERAPY
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
- (2008) Cheol-Min Park et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells
- (2008) Henning Schulze-Bergkamen et al. WORLD JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation